DOCSLIB.ORG

Coinfection and Other Clinical Characteristics of COVID-19 In

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Coinfection and Other Clinical Characteristics of COVID-19 In Coinfection and Other Clinical Characteristics of COVID-19 in Children Qin Wu, MD,a,p Yuhan Xing, MD,b,p Lei Shi, MB,a,p Wenjie Li, MS,a Yang Gao, MS,a Silin Pan, PhD, MD,a Ying Wang, MS,c Wendi Wang, MS,a Quansheng Xing, PhD, MDa BACKGROUND AND OBJECTIVES: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is abstract a newly identified pathogen that mainly spreads by droplets. Most published studies have been focused on adult patients with coronavirus disease 2019 (COVID-19), but data concerning pediatric patients are limited. In this study, we aimed to determine epidemiological characteristics and clinical features of pediatric patients with COVID-19. METHODS: We reviewed and analyzed data on pediatric patients with laboratory-confirmed COVID-19, including basic information, epidemiological history, clinical manifestations, laboratory and radiologic findings, treatment, outcome, and follow-up results. RESULTS: A total of 74 pediatric patients with COVID-19 were included in this study. Of the 68 case patients whose epidemiological data were complete, 65 (65 of 68; 95.59%) were household contacts of adults. Cough (32.43%) and fever (27.03%) were the predominant symptoms of 44 (59.46%) symptomatic patients at onset of the illness. Abnormalities in leukocyte count were found in 23 (31.08%) children, and 10 (13.51%) children presented with abnormal lymphocyte count. Of the 34 (45.95%) patients who had nucleic acid testing results for common respiratory pathogens, 19 (51.35%) showed coinfection with other pathogens other than SARS-CoV-2. Ten (13.51%) children had real-time reverse transcription polymerase chain reaction analysis for fecal specimens, and 8 of them showed prolonged existence of SARS-CoV-2 RNA. CONCLUSIONS: Pediatric patients with COVID-19 presented with distinct epidemiological, clinical, and radiologic characteristics from adult patients. Nearly one-half of the infected children had coinfection with other common respiratory pathogens. It is not uncommon for pediatric patients to have prolonged fecal shedding of SARS-CoV-2 RNA during the convalescent phase. ’ aQingdao Women and Children’s Hospital of Qingdao University, Qingdao, China; bDepartment of Pediatrics, Faculty WHAT S KNOWN ON THIS SUBJECT: Severe acute of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China; and cWuhan respiratory coronavirus 2 is a newly identified pathogen Children’s Hospital and Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China that mainly spreads by droplets. Most published studies *Contributed equally as co-first authors. have been focused on adult patients with coronavirus Drs Q. Xing, W. Wang, and Y. Wang conceptualized and designed the study, drafted the initial disease 2019, but data concerning pediatric patients are manuscript, and reviewed and revised the manuscript; Drs Wu and Y. Xing and Ms Shi limited. conceptualized and designed the study, coordinated and supervised data collection, and critically WHAT THIS STUDY ADDS: Children with coronavirus reviewed the manuscript for important intellectual content; Drs Li, Gao, and Pan designed the data disease 2019 presented with distinct clinical collection instruments, collected data, conducted the initial analyses, and reviewed and revised the characteristics from adult patients. Notably, coinfection manuscript; and all authors approved the final manuscript as submitted and agree to be with other respiratory pathogens were common in accountable for all aspects of the work. pediatric patients, highlighting the importance for the DOI: https://doi.org/10.1542/peds.2020-0961 screening of severe acute respiratory syndrome Accepted for publication May 1, 2020 coronavirus 2. Address correspondence to Quansheng Xing, PhD, MD, Department of Paediatrics, Qingdao Women and Children’s Hospital of Qingdao University, No. 6 Tongfu Rd, Qingdao 266034, China. To cite: Wu Q, Xing Y, Shi L, et al. Coinfection and E-mail: [email protected] Other Clinical Characteristics of COVID-19 in Children. Pediatrics. 2020;146(1):e20200961 Downloaded from www.aappublications.org/news by guest on September 27, 2021 PEDIATRICS Volume 146, number 1, July 2020:e20200961 ARTICLE During the last 3 months, we faced age, weight, time of onset, time of mild pneumonia, severe pneumonia, the fast-growing outbreak of diagnosis by SARS-CoV-2 nucleic and critical cases (acute respiratory coronavirus disease 2019 (COVID-19) acid test, and date of admission distress syndrome and severe acute that swept through China and rapidly and discharge), epidemiological respiratory syndrome [SARS]). Mild spread to all over the world. The history, clinical manifestations, pneumonia was further subgrouped etiologic agent, severe acute laboratory and radiologic findings, into subclinical type and clinical type respiratory syndrome coronavirus 2 treatment, outcome, and follow- on the basis of the clinical (SARS-CoV-2), was identified as up data were recorded with manifestations. a novel pathogen highly contagious to standardized data collection forms. the general population, with This study was approved by the Statistical Analysis a relatively high mortality rate. By the institutional review board of the Categorical data were expressed as end of April 2020, .3 million ethics committee of the Qingdao a number and percentage, and confirmed cases of COVID-19 were Women and Children’s Hospital continuous data were expressed reported in over 200 countries and (QFELL-KY-2020-11), and written as a median with a range or regions globally, causing .200 000 informed consent was obtained from interquartile. Statistical analyses were 1 deaths. Currently, the epidemic patients’ legal guardians before performed by using SAS software (SAS center has been shifted to the United enrollment. 9.4; SAS Institute, Inc, Cary, NC). States and Europe. In early studies on COVID-19, Chinese researchers2–5 Determination of Exposure History Role of the Funding Source fi have provided rst-hand knowledge Detailed epidemiological data of all The funder of the study had no and valuable treatment experiences case patients were collected and role in study design, data collection, fi for other countries to learn from, but classi ed according to whether the data analysis, data interpretation, most of the studies were targeted at case patients were household or writing of this article. The fi adult patients. The majority of contacts of con rmed adult patients, corresponding authors had full publication on pediatric cases of the sequence of infection within the access to all the data in the COVID-19 during the early stage of families, and whether the infected study and had final responsibility the disease were case reports or children transmitted the virus to for the decision to submit for studies with a relatively small sample others. publication. size.6–11 To determine the spectrum fi of the disease in children, we Laboratory Con rmation collected and analyzed Confirmation of COVID-19 was based RESULTS epidemiological, clinical, laboratory, on a positive result for real-time Basic Characteristics and radiologic data of 74 pediatric reverse transcription polymerase COVID-19 cases in 2 locations of chain reaction (RT-PCR) testing of None of the 74 infected children had northern and southern China. We SARS-CoV-2 in nasopharyngeal comorbidities. Detailed data of the hope our study will be used to swabs by hospital laboratory and baseline characteristics of the further the understanding of SARS- was double confirmed by the local patients are listed in Table 2, and CoV-2 infection in children and Centers for Disease Control and the time line of disease progression provide an insight to treatment Prevention using the same RT-PCR including the date of admission, strategies and prophylactic control protocol. A final decision on COVID- diagnosis, and discharge and the of the disease. 19 diagnosis was made according to final date of follow-up are shown World Health Organization interim in Fig 1. guidance.12 METHODS Epidemiological Characteristics fi Diagnosis Classi cation Complete information of exposure Data Sources According to the experts’ consensus history was collected from 68 of From January 20 to February 27 of statement on the diagnosis, the 74 patients (91.9%). Except for 2020, we retrospectively reviewed treatment, and prevention of 2019 3 sporadic cases, 65 (65 of 68; electronic medical records of 74 novel coronavirus infection in 95.6%) case patients were pediatric COVID-19 cases admitted in children issued by the Group of household contacts of adults whose the Qingdao Women and Children’s Respirology of the Chinese symptoms developed earlier and Hospital and Wuhan Children’s Pediatric Society,13 patients were the last confirmed case within the Hospital, including data recorded classified into 5 types (Table 1): family, including 18 (27.7%) being during hospitalization and the follow- asymptomatic infection, acute the second infected family member, up period. Baseline information (sex, upper respiratory tract infection, 23 (35.4%) being the third, 14 Downloaded from www.aappublications.org/news by guest on September 27, 2021 2 WU et al TABLE 1 Definitions of Clinical Types of COVID-19 in Children Diagnostic Criteria Asymptomatic infection Positive RT-PCR test results for SARS-CoV-2 Without manifestations of clinical symptoms Without abnormal chest imaging findings Acute upper respiratory tract Upper respiratory symptoms (eg, fever, cough, pharyngeal pain, nasal congestion, fatigue, headache, and myalgia)
Load more

Recommended publications
  • CONNECTION the Official Newsletter of Zhejiang University Issue 16 Feb.2020
    CONNECTION The Official Newsletter of Zhejiang University Issue 16 Feb.2020 COVID-19 Special Issue Stand Strong Message from Editor-in-Chief CONNECTION Welcome to the special COVID-19 issue of Issue 16 CONNECTION, which highlights the efforts and contributions of ZJU community in face of the epidemic. As a group, they are heroes in harm's way, givers and doers who respond swiftly to the need of our city, our country and the world. When you read their stories, you'll recognize the strength and solidarity that define all ZJUers. ZJU community has demonstrated its courage and resilience in the battle against the novel coronavirus. At this time, let us all come together to protect ourselves and our loved ones, keep all those who are at the front lines in our prayers and pass on our gratitude to those who have joined and contributed to the fight against the virus. Together, we will weather this crisis. LI Min, Editor-in-Chief Director, Office of Global Engagement Editorial office : Global Communications Office of Global Engagement, Zhejiang University 866 Yuhangtang Road, Hangzhou, P.R. China 310058 Phone: +86 571 88981259 Fax: +86 571 87951315 Email: [email protected] Edited by : CHEN Weiying, AI Ni Designed by : HUANG Zhaoyi Material from Connection may be reproduced accompanied with appropriate acknowledgement. CONTENTS Faculty One of the heroes in harm’s way: LI Lanjuan 03 ZJU medics answered the call from Wuhan 04 Insights from ZJU experts 05 Alumni Fund for Prevention and Control of Viral Infectious Diseases set up 10 Alumni community mobilized in the battle against COVID-19 11 Education Classes start online during the epidemic 15 What ZJUers feel about online learning 15 Efforts to address concerns, avoid misinformation 17 International World standing with us 18 International students lending a hand against the epidemic 20 What our fans say 21 FacultyFaculty ZJU community has taken on the responsibility to join the concertedZJU community efforts has takenagainst on thethe responsibility spreadto join the of concerted the virus.
    [Show full text]
  • HIV and Hepatitis C Coinfection a New Era of Treatment for People with HIV and Hepatitis C Coinfection
    HIV and Hepatitis C Coinfection A new era of treatment for people with HIV and Hepatitis C Coinfection: What is HIV/Hepatitis C Coinfection? HIV and Hepatitis C coinfection means that you are living with both HIV and Hepatitis C. HIV aects your immune system and Hepatitis C (often called Hep C or HCV) is an infection that aects your liver. Hepatitis C has been one of the leading causes of illness for people with HIV – but now that is changing! 1. If you have HIV/ Hepatitis C Coinfection you are not alone. • About 30% of people living with HIV are coinfected with Hepatitis C. • The rate is even higher (50-90%) for people living with HIV who have a history of injection drug use and are coinfected with Hepatitis C. Gay men living with HIV should know the facts. Men who have sex with men who are living with HIV are at increased risk of getting Hepatitis C during sex. The risk is highest when blood is present during sex, for example during anal intercourse or rough sex. Using condoms, lots of lube and preventing bleeding during sex can help protect you from Hepatitis C. New treatments for Hepatitis C have changed everything. Old Treatments New Treatments • Not very eective • 90 -100% cure rate • Serious side eects • Few or no side eects • Risks outweighed benefits • Almost everyone can for most people benefit from treatment If you were not eligible for the old treatments or if you had treatment and it didn’t work, you will most likely be able to benefit from the new treatment! 2.
    [Show full text]
  • 1. Sars-Cov Nucleocapsid Protein Epitopes and Uses Thereof
    www.engineeringvillage.com Citation results: 500 Downloaded: 4/24/2020 1. SARS-COV NUCLEOCAPSID PROTEIN EPITOPES AND USES THEREOF KELVIN, David; PERSAD, Desmond; CAMERON, Cheryl; BRAY, Kurtis, R.; LOFARO, Lori, R.; JOHNSON, Camille; SEKALY, Rafick-Pierre; YOUNES, Souheil-Antoine; CHONG, Pele Assignee: UNIVERSITY HEALTH NETWORK; BECKMAN COULTER, INC.; UNIVERSITE DE MONTREAL; NATIONAL HEALTH RESEARCH INSTITUTES Publication Number: WO2005103259 Publication date: 11/03/2005 Kind: Patent Application Publication Database: WO Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data Provider: Engineering Village 2. SARS-CoV-specific B-cell epitope and applications thereof Wu, Han-Chung; Liu, I-Ju; Chiu, Chien-Yu Assignee: National Taiwan University Publication Number: US20060062804 Publication date: 03/23/2006 Kind: Utility Patent Application Database: US Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data Provider: Engineering Village 3. A RECOMBINANT SARS-COV VACCINE COMPRISING ATTENUATED VACCINIA VIRUS CARRIERS QIN, Chuan; WEI, Qiang; GAO, Hong; TU, Xinming; CHEN, Zhiwei; ZHANG, Linqi; HO, David, D. Assignee: INSTITUTE OF LABORATORY ANIMAL SCIENCE OF CHINESE ACADEMY OF MEDICAL SCIENCES; THE AARON DIAMOND AIDS RESEARCH CENTER; QIN, Chuan; WEI, Qiang; GAO, Hong; TU, Xinming; CHEN, Zhiwei; ZHANG, Linqi; HO, David, D. Publication Number: WO2006079290 Publication date: 08/03/2006 Kind: Patent Application Publication Database: WO Patents Compilation and indexing terms, 2020 LexisNexis Univentio B.V. Data
    [Show full text]
  • HIV & Hepatitis Co-Infection
    HIV & Hepatitis Co‐infection HIV/STI Project Family and Community Health Area PAHO/WHO Viral Hepatitis & HIV co‐infection • HIV infection alters the course of VH • VH may alter the progression of HIV infection • Limited knowledge of actual extent of problem • Shared routes of transmission • HBV, HCV and HAV infections more common • HDV requires HBV as a helper virus • HEV infection carries a high mortality among pregnant women • CMV, HSV and EBV hepatitis can be found in patients with AIDS Hepatitis B and HIV co‐infection Hepatitis B and HIV co‐infection • Common: 70 – 90% (past or active) among HIV + • Frequent among MARP’s • Reduced spontaneous clearance among HIV+ • Chronic infection 10 times higher than among HIV‐ • Vertical transmission of HBV does occur • Immune deficiency favors HBV reactivation • Increased risk of cirrhosis & end‐stage liver disease • Significant hepatic mortality among HIV+ Hepatitis B and HIV co‐infection • All HIV+ should be tested for HBsAg • If HBsAg neg check for prior infection (HBcAb & HBsAb) • cAb+ = risk of reactivation if there is immune suppression • Loss of sAb may occur over time (waned response) • Administer vaccine booster (3 doses) • Test for HCV • Vaccinate against HAV HBV/HIV co‐infection management • Suppress HBV replication & minimize damage • Avoid alcohol, acetaminophen, hepatotoxic drugs • Indefinite treatment often required • Fully suppressive ART recommended (early initiation) • Behavioral changes needed to prevent transmission • Remind public about efficiency of HBV transmission • Vaccinate
    [Show full text]
  • The Potential Impact of Coinfection on Antimicrobial
    Review The potential impact of coinfection on antimicrobial chemotherapy and drug resistance 1* 2,3* 4 5 6 Ruthie B. Birger , Roger D. Kouyos , Ted Cohen , Emily C. Griffiths , Silvie Huijben , 1,7 8 1,9 1,9* Michael J. Mina , Victoriya Volkova , Bryan Grenfell , and C. Jessica E. Metcalf 1 Department of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ, USA 2 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zu¨ rich, University of Zu¨ rich, Zu¨ rich, Switzerland 3 Institute of Medical Virology, University of Zu¨ rich, Zu¨ rich, Switzerland 4 Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA 5 Department of Entomology, Gardner Hall, Derieux Place, North Carolina State University, Raleigh, NC 27695-7613, USA 6 ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clı´nic –Universitat de Barcelona, Barcelona, Spain 7 Medical Scientist Training Program, Emory University School of Medicine, Atlanta, GA, USA 8 Department of Diagnostic Medicine/Pathobiology, Institute of Computational Comparative Medicine, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USA 9 Fogarty International Center, National Institutes of Health, Bethesda, MD, USA Across a range of pathogens, resistance to chemothera- One way to classify the diversity of possible interactions py is a growing problem in both public health and animal between pathogens is to set them on a spectrum of syner- health. Despite the ubiquity of coinfection, and its po- gistic to antagonistic. In synergistic interactions, the with- tential effects on within-host biology, the role played in-host growth rate of one parasite will increase in the by coinfecting pathogens on the evolution of resistance presence of the other, while in antagonistic interactions, and efficacy of antimicrobial chemotherapy is rarely the presence of one pathogen will limit the growth rate of considered.
    [Show full text]
  • Lopinavir/Ritonavir for COVID-19: a Living Systematic Review Doi: 10.5867/Medwave.2020.06.7966
    Lopinavir/ritonavir for COVID-19: A living systematic review doi: 10.5867/medwave.2020.06.7966 Appendix 3: Included, excluded and ongoing studies - Lopinavir/ritonavir for COVID-19: A living systematic review Included randomised trials LOTUS China (1,2) Details or comments REFERENCES Publication thread for LOTUS China Epistemonikos Chen et al (1) Type: Journal article Epistemonikos | DOI ChiCTR2000029387 (2) Type:Trial registry (Chinese Clinical Trial Registry) Epistemonikos | DOI (not available) STUDY DESIGN QUOTE: ☑Randomised trial Single centre , open-label, individually randomized, controlled trial; ☐Comparative, non- randomised Eligible patients were randomly assigned in a 1:1 ratio; ☐Non-comparative study To balance the distribution of oxygen support between the two groups as an indicator of severity of respiratory failure, randomization was stratified on the basis of respiratory support methods at the time of enrollment: no oxygen support or oxygen support with nasal duct or mask, or high-flow oxygen, noninvasive ventilation, or invasive ventilation including ECMO. The permuted block (four patients per block) randomization sequence, including stratification, was prepared by a statistician not involved in the trial, using SAS software, version 9.4 (SAS Institute). POPULATION: INCLUSION QUOTE: CRITERIA Patients were assessed for eligibility on the basis of a positive reverse-transcriptase– ☐COVID-19 polymerase-chain-reaction (RT-PCR) assay) for SARS-CoV-2 in a respiratory tract ☑COVID-19 pneumonia sample Male and nonpregnant female patients 18 years of age or older were eligible if they had a diagnostic specimen that was positive on RT-PCR, had pneumonia ☐Severe COVID-19 pneumonia confirmed by chest imaging, had an oxygen saturation of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen to the fraction 1 / 27 Lopinavir/ritonavir for COVID-19: A living systematic review doi: 10.5867/medwave.2020.06.7966 of inspired oxygen at or below 300 mg Hg.
    [Show full text]
  • Prevalence of Sexually Transmitted Pathogen Coinfections in High Risk-Human Papillomaviruses Infected Women in Busan
    Biomedical Science Letters 2019, 25(4): 390 ~397 Original Article https://doi.org/10.15616/BSL.2019.25.4.390 eISSN : 2288-7415 Prevalence of Sexually Transmitted Pathogen Coinfections in High Risk-Human Papillomaviruses Infected Women in Busan Sun Hee Choi 1, *, Hyunwoo Jin 2, ** and Kyung Eun Lee 2,†,** 1Department of Laboratory Medicine, i-Angel Women's Clinic, Busan 46023, Korea 2Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Busan 46252, Korea High risk-human papillomavirus (HR-HPV) is known to be a major cause of cervical cancer, and coinfection of sexually transmitted pathogen (STP) has been reported to cause persistent HPV infection. However, the relationship between HPV and STP coinfection remains unclear. The purpose of this study was to analyze the coinfection rate with STP in high-risk human papillomavirus infected women in Busan and to collect basic data for the prevention of cervical lesions. This study was carried out in 355 women who had concurrent HPV and STP screening at Busan local hospital between January 2016 and December 2017. HPV and STP coinfection was found in 187 (52.7%) out of 355 cases. HR-HPV and STP coinfection was 82.9% higher than LR-HPV and STP coinfections 17.1%. In HR-HPV infection, Ureaplasma species was the most common pathogen (47.1%), followed by C. trachomatis (21.9%) and Mycoplasma species (12.3%). In the analysis of HR-HPV genotype according to STP, HPV 16 (12.0%) was the most frequent, followed by HPV 58 (11.6%), HPV 39 (11.1%) and HPV 52 (10.2%), but HPV 18 showed a low coinfection rate of 1.3%.
    [Show full text]
  • Legionella Coinfection in a Patient with COVID- 19 Pneumonia
    Open Access Case Report DOI: 10.7759/cureus.17356 Review began 06/29/2021 Review ended 08/14/2021 Legionella Coinfection in a Patient With COVID- Published 08/21/2021 © Copyright 2021 19 Pneumonia Subedi et al. This is an open access 1, 2, 3 1, 2, 3, 4 article distributed under the terms of the Yogesh Subedi , Christopher J. Haas Creative Commons Attribution License CC-BY 4.0., which permits unrestricted 1. Medicine, MedStar Union Memorial Hospital, Baltimore, USA 2. Medicine, MedStar Franklin Square Medical Center, use, distribution, and reproduction in any Baltimore, USA 3. Medicine, MedStar Harbor Hospital, Baltimore, USA 4. Medicine, George Washington University medium, provided the original author and School of Medicine and Health Sciences, Washington, DC, USA source are credited. Corresponding author: Yogesh Subedi, [email protected] Abstract Bacterial superinfection is a well-reported complication of viral pneumonia leading to significantly increased morbidity and mortality. Such superinfections have been reported in patients with pathogenic coronaviruses including severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS), but there are scant reports pertaining to superinfection in the context of coronavirus disease 2019 (COVID-19). We report a case of a middle-aged man who presented with worsening shortness of breath in the context of COVID-19 complicated by superimposed Legionella pneumophilia pneumonia. This case serves to highlight the possibility of bacterial superinfections and to be aware of such possibilities when patients are not responding to standard courses of treatment for COVID-19 as quick clinical deterioration is likely to develop. Categories: Internal Medicine, Infectious Disease, Rheumatology Keywords: covid-19, coinfection, legionella, dexamethasone, remdesivir, azithromycin, rheumatoid arthritis Introduction At the end of 2019, a novel coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, China [1].
    [Show full text]
  • Clinical Impact of Respiratory Syncytial Virus Infection on Children Hospitalized for Pertussis Ruimu Zhang and Jikui Deng*
    Zhang and Deng BMC Infectious Diseases (2021) 21:161 https://doi.org/10.1186/s12879-021-05863-9 RESEARCH ARTICLE Open Access Clinical impact of respiratory syncytial virus infection on children hospitalized for pertussis Ruimu Zhang and Jikui Deng* Abstract Background: Although Respiratory syncytial virus (RSV) is one of the common pathogens in children with pertussis and viral coinfection, the clinical impact of RSV infection on pertussis remains unclear. We compared clinical characteristics and sought differences between infants with single Bordetella pertussis (B. pertussis) infection and those with RSV coinfection. Methods: We enrolled 80 patients with pertussis who were hospitalized in Shenzhen Children’s Hospital from January 2017 to December 2019. Respiratory tract samples were tested for B. pertussis with real-time polymerase chain reaction and respiratory viruses with immunofluorescence assay. Clinical data were obtained from hospital records and collected using a structured questionnaire. Results: Thirty-seven of 80 patients had B. pertussis infection alone (pertussis group) and 43 had RSV-pertussis coinfection (coinfection group). No significant differences were found with regard to sex, body weight, preterm birth history, pertussis vaccination, symptoms, presence of pneumonia, or lymphocyte count between the 2 groups. Univariate analysis showed patients with RSV coinfection were older (median, 4.57 months vs 4.03 months, p = 0.048); more commonly treated with β-lactam antibiotics (21% vs 5%, p = 0.044); had higher rates of wheezes (40% vs 14%, p = 0.009) and rales (35% vs 14%, p = 0.028) on chest auscultation, a higher rate of readmission (40% vs 11%, p = 0.004), and a longer hospital stay (median, 10 days vs 7 days, p = 0.002).
    [Show full text]
  • Hepatitis C Coinfection
    © National HIV Curriculum PDF created September 24, 2021, 3:49 pm Hepatitis C Coinfection This is a PDF version of the following document: Module 4: Co-Occurring Conditions Lesson 6: Hepatitis C Coinfection You can always find the most up to date version of this document at https://www.hiv.uw.edu/go/co-occurring-conditions/hepc-coinfection/core-concept/all. Background and Epidemiology General Hepatitis C Epidemiology Hepatitis C virus (HCV) is a single-stranded RNA virus that is an important cause of cirrhosis, liver failure, and hepatocellular carcinoma. Globally, an estimated 170 million people are living with HCV. In the United States, the most recent prevalence data from a National Health and Nutrition Examination Survey (NHANES) estimated 2.4 million persons were HCV RNA positive and 4.1 million were HCV antibody positive.[1] The CDC estimates that at least two-thirds of all persons with active HCV in the United States were born between 1945 and 1965.[2] Since 2002, however, the number of new HCV cases among younger persons has increased significantly, leading to a bimodal distribution.[3,4,5] Although the annual number of contemporary new HCV infections in the United States is markedly lower than in the 1980s (Figure 1), the incidence increased significantly from 2010 through 2018 (Figure 2).[5,6] The greatest relative increases occurred among adults 20 to 39 years and the burgeoning acute HCV infection rates in the United States in recent years correlates directly with the ongoing major opioid epidemic.[5] Epidemiology of HIV-HCV
    [Show full text]
  • HIV and Human Coronavirus Coinfections: a Historical Perspective
    viruses Review HIV and Human Coronavirus Coinfections: A Historical Perspective Palesa Makoti and Burtram C. Fielding * Molecular Biology and Virology Research Laboratory, Department of Medical Biosciences, University of the Western Cape, Cape Town 7535, South Africa; [email protected] * Correspondence: bfi[email protected]; Tel.: +27-21-959-2949 Received: 21 May 2020; Accepted: 2 August 2020; Published: 26 August 2020 Abstract: Seven human coronaviruses (hCoVs) are known to infect humans. The most recent one, SARS-CoV-2, was isolated and identified in January 2020 from a patient presenting with severe respiratory illness in Wuhan, China. Even though viral coinfections have the potential to influence the resultant disease pattern in the host, very few studies have looked at the disease outcomes in patients infected with both HIV and hCoVs. Groups are now reporting that even though HIV-positive patients can be infected with hCoVs, the likelihood of developing severe CoV-related diseases in these patients is often similar to what is seen in the general population. This review aimed to summarize the current knowledge of coinfections reported for HIV and hCoVs. Moreover, based on the available data, this review aimed to theorize why HIV-positive patients do not frequently develop severe CoV-related diseases. Keywords: coronaviruses; HIV; COVID-19; SARS-CoV-2; MERS-CoV; immunosuppression; immune response; coinfection 1. Introduction With the rapid advancement of molecular diagnostic tools, our understanding of the etiological agents of respiratory tract infections (RTIs) has advanced rapidly [1]. Researchers now know that lower respiratory tract infections (LRTIs)—caused by viruses—are not restricted to the usual suspects, such as respiratory syncytial virus (RSV), parainfluenza viruses (PIVs), adenovirus, human rhinoviruses (HRVs) and influenza viruses.
    [Show full text]
  • Onset of Opportunistic Infections in Patients Co-Infected by HTLV-1 and HIV-1, with High CD4+ Cells Count
    BJID 2009; 13 (August) 311 Onset of Opportunistic Infections in Patients Co-Infected by HTLV-1 and HIV-1, With High CD4+ Cells Count Catarina Regis, Adriano Oliveira and Carlos Brites Universidade Federal da Bahia, Hospital Universitário Prof. Edgard Santos, Virology Research Laboratory; Salvador, BA, Brazil We reported two cases of patients with coinfection by human immunodeficiency virus (HIV) type 1 and human T-cell lymphotropic virus (HTLV) type I who developed opportunistic infections despite of relatively high CD4+ cells count. These cases showed clinical evidence to consider an earlier antiretroviral treatment for coinfected patientes regardless CD4+ cells counts. Key-Words: HIV-1/HTLV-1 co-infection, Opportunistic infections, CD4. Human T-cell lymphotropic virus type I (HTLV-I) is Disease Clinic at Federal University of Bahia Hospital in associated with adult T-cell leukemia/lymphoma (ATL), HTLV- January 1999. She had a history of unprotected sexual relations I-associated myelopathy (HAM/TSP), and typical with a intravenous drug abuser. Her main complaints at dermatological and immunological abnormalities. admission were lower extremities weakness for 3 years with Seroprevalence studies in the USA, Europe and developing progressive gait disability and urinary incontinence. She also countries have demonstrated a high frequency (5 -15%) of complaint about pruritus associated to disseminated skin HTLV-I coinfection among HIV-1 infected patients [1-3]. These lesions for four months. Neurological exam revealed ataxia, rates are, at least, 100 to 500 higher than that found in general hypereflexia, and bilateral Babinski’s sign. Diagnostic population [1,2]. In Salvador, Bahia (a Northeast Brazilian suspicions were HAM/TSP and Norwegian scabies.
    [Show full text]